Novartis (NOVN) Q3 2024 earnings summary

Executive summary

• Achieved 10% net sales growth and 20% core operating income growth in Q3 2024, with strong performance across key brands, innovation milestones, and a third upgrade to full-year 2024 guidance.

• Net sales reached $12.8 billion in Q3 and $37.2 billion for the nine months, with core operating income at $5.1 billion in Q3 and $14.6 billion for nine months.

• Completed Sandoz spin-off, transforming into a pure-play innovative medicines business focused on four core therapeutic areas.

• Key product launches and regulatory milestones included Kisqali FDA approval in early breast cancer, Fabhalta accelerated approval in IgA nephropathy, and Pluvicto filing acceptance for new indications.

• On track for mid-term guidance: 5%+ sales CAGR (2023–2028) and 40%+ core operating margin by 2027.

Financial highlights

• Q3 net sales: $12.8 billion (+10% cc); nine months: $37.2 billion (+11% cc); Q3 core operating income: $5.1 billion (+20% cc); nine months: $14.6 billion (+20% cc).

• Q3 operating income: $3.6 billion (+106%); net income: $3.2 billion (+121% cc); EPS: $1.58 (+127% cc); core EPS: $2.06 (+20% cc).

• Free cash flow: $6.0 billion in Q3 (+18%); $12.6 billion for nine months (+15%).

• Core margin improved to 40.1% in Q3 (+340 bps year-over-year); nine months: 39.4%.

• Net debt at September 30, 2024: $16.3 billion, up from $10.2 billion at year-end 2023.

Outlook and guidance

• Full-year 2024 net sales expected to grow low double-digit (previously high single to low double-digit); core operating income expected to grow high teens (previously mid to high teens).

• Assumes no US generic entries for Tasigna, Promacta, or Entresto in 2024; generics expected mid-2025 for modeling.

• Currency expected to have a mild negative impact: -1% to -2% on net sales and -2% to -6% on core operating income for 2024.

• Core tax rate expected around 16.2% for the full year.

• Confident in achieving 5% sales CAGR (2023–2028) and 40%+ core margin by 2027.